Prevention and treatment of exacerbations of non-CF bronchiectasis

European Respiratory Monograph

Volumn 60, Issue , 2013, Pages 127-136

  Rademacher, Jessica ^a   Ringshausen, Felix C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antibiotics; Bronchiectasis; Exacerbation; Prevention; Prophylaxis; Treatment

Indexed keywords

AMIKACIN; AMOXICILLIN; AZITHROMYCIN; AZTREONAM; CIPROFLOXACIN; COLISTIN; ERYTHROMYCIN; GENTAMICIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; LEUKOTRIENE B4; LEVOFLOXACIN; PLACEBO; TOBRAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL LOAD; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE ERADICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; HUMAN; INFECTION RISK; LUNG CLEARANCE; MORBIDITY; MUCOCILIARY CLEARANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PSEUDOMONAS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

EID: 84878425086     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10018212     Document Type: Article

References (71)

1. Wilson R. A vicious circle hypothesis operating during infective exacerbations of chronic bronchitis. Monaldi Arch Chest Dis 1994; 49: 159-164.
2. Wilson CB, Jones PW, O'Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10: 1754-1760.
3. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010; 19: 113-118.
4. Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: Suppl. 1, i1-58.
5. Goeminne PC, Scheers H, Decraene A, et al. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012; 13: 21.
6. Bott J, Moran F. Physiotherapy and NIPPV. In: Simonds AK, ed. Non-Invasive Respiratory Support. London: Chapman and Hall, 1995; pp. 133-142.
7. Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005; 99: 27-31.
8. Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012; 106: 661-667.
9. Daviskas E, Anderson SD, Gomes K, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005; 10: 46-56.
10. Gjoerup J, Hilberg O, Bendstrup E. Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults. Respirology 2012; 17: 927-932.
11. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2006; 2: CD002996.
12. Bradley J, Moran F, Greenstone M. Physical training for bronchiectasis. Cochrane Database Syst Rev 2002; 3: CD002166.
13. Liaw MY, Wang YH, Tsai YC, et al. Inspiratory muscle training in bronchiectasis patients: a prospective randomized controlled study. Clin Rehabil 2011; 25: 524-536.
14. Naraparaju S, Vaishali K, Venkatesan P, et al. A comparison of the Acapella and a threshold inspiratory muscle trainer for sputum clearance in bronchiectasis-a pilot study. Physiother Theory Pract 2010; 26: 353-357.
15. Figueiredo PH, Zin WA, Guimarães FS. Flutter valve improves respiratory mechanics and sputum production in patients with bronchiectasis. Physiother Res Int 2012; 17: 12-20.
16. Crockett AJ, Cranston JM, Latimer KM, et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev 2001; 1: CD001289.
17. Furumoto A, Ohkusa Y, Chen M, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008; 26: 4284-4289.
18. Chang CC, Singleton RJ, Morris PS, et al. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009; 2: CD006316.
19. Lasserson T, Holt K, Greenstone M. Oral steroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst Rev 2001; 4: CD002162.
20. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005; 60: 239-243.
21. Kapur N, Bell S, Kolbe J, et al. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009; 1: CD000996.
22. Martinez-García MA, Perpiñá-Tordera M, Román-Sánchez P, et al. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med 2006; 100: 1623-1632.
23. Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 2008; 117: 393-405.
24. Anwar GA, Bourke SC, Afolabi G, et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008; 102: 1494-1496.
25. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-667.
26. Wilson R, Wells AU. Azithromycin in bronchiectasis: when should it be used? Lancet 2012; 380: 627-629.
27. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev 2007; 2: CD001392.
28. Tsang KW, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999; 13: 361-364.
29. Hill SL, Burnett D, Hewetson KA, et al. The response of patients with purulent bronchiectasis to antibiotics for four months. Q J Med 1988; 66: 163-173.
30. Chalmers JD, Smith MP, McHugh BJ, et al. Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186: 657-665.
31. Angrill J, AgustíC, De Celis R, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164: 1628-1632.
32. Angrill J, AgustíC, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 15-19.
33. Frederiksen B, Lanng S, Koch C, et al. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996; 21: 153-158.
34. Mandal P, Sidhu MK, Donaldson LS, et al. Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. QJM 2013; 106: 27-33.
35. Ratjen F, Munck A, Kho P, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE Trial. Thorax 2010; 65: 286-291.
36. Drobnic ME, Suñé P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39: 39-44.
37. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127: 1420-1426.
38. Steinfort DP, Steinfort C. Effect of long-term nebulized colistin of lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 2007; 37: 495-498.
39. Dhar R, Anwar GA, Bourke SC, et al. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax 2010; 65: 553.
40. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care 2008; 178: 921-928.
41. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013; 41: 1107-1115.
42. Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491-499.
43. Antoniu SA, Trofor AC. Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy. Expert Opin Pharmacother 2011; 12: 1191-1194.
44. Ho PL, Chan KN, Ip MS, et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steadystate bronchiectasis. Chest 1998; 114: 1594-1598.
45. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132: 1565-1572.
46. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009; 4: CD004197.
47. Davies G, Wells AU, Doffman S, et al. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006; 28: 974-979.
48. White L, Mirrani G, Grover M, et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012; 106: 356-360.
49. Lasserson T, Holt K, Evans D, et al. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst Rev 2001; 4: CD002163.
50. Sheikh A, Nolan D, Greenstone M. Long-acting b2-agonists for bronchiectasis. Cochrane Database Syst Rev 2001; 4: CD002155.
51. Corless JA, Warburton CJ. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. Cochrane Database Syst Rev 2000; 4: CD002174.
52. Steele K, Greenstone M, Lasserson JA. Oral methyl-xanthines for bronchiectasis. Cochrane Database Syst Rev 2001; 1: CD002734.
53. Pizzutto SJ, Upham JW, Yerkovich ST, et al. Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2010; 4: CD007525.
54. Corless JA, Warburton CJ. Surgery vs non-surgical treatment for bronchiectasis. Cochrane Database Syst Rev 2000; 3: CD002180.
55. Sharples LD, Edmunds J, Bilton D, et al. A randomised controlled crossover trial of nurse practitioner versus doctor led outpatient care in a bronchiectasis clinic. Thorax 2002; 57: 661-666.
56. Chalmers JD, McHugh BJ, Docherty C, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013; 68: 39-47.
57. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 400-407.
58. O'Brien C, Guest PJ, Hill SL, et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55: 635-642.
59. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
60. Kapur N, Masters IB, Chang AB. Exacerbations in noncystic fibrosis bronchiectasis: clinical features and investigations. Respir Med 2009; 103: 1681-1687.
61. Finklea JD, Khan G, Thomas S, et al. Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir Med 2010; 104: 816-821.
62. Hoffken G, Lorenz J, Kern W, et al. Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen unteren Atemwegsinfektionen sowie ambulant erworbener Pneumonie Update 2009. S3-Leitlinie der Paul-Ehrlich-Gesellschaft fur Chemotherapie, der Deutschen Gesellschaft fur Pneumologie und Beatmungsmedizin, der Deutschen Gesellschaft fur Infektiologie und vom Kompetenznetzwerk CAPNETZ [Epidemiology, diagnosis, antimicrobial therapy and management of communityacquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany]. Pneumologie 2009; 63: e1-e68.
63. Pletz MW, McGee L, Burkhardt O, et al. Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy. Eur J Clin Microbiol Infect Dis 2005; 24: 58-60.
64. Pines A, Raafat H, Siddiqui GM, et al. Treatment of severe pseudomonas infections of the bronchi. Br Med J 1970; 1: 663-665.
65. Pines A, Khaja G, Raafat H, et al. Preliminary clinical experience with ticarcillin (BRL 2288) in 101 patients treated for severe respiratory infections. Chemotherapy 1974; 20: 39-44.
66. Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130: 1503-1510.
67. Simonds AK, Elliott MW. Outcome of domiciliary nasal intermittent positive pressure ventilation in restrictive and obstructive disorders. Thorax 1995; 50: 604-609.
68. Holland AE, Denehy L, Ntoumenopoulos G, et al. Non-invasive ventilation assists chest physiotherapy in adults with acute exacerbations of cystic fibrosis. Thorax 2003; 58: 880-884.
69. Young AC, Wilson JW, Kotsimbos TC, et al. Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. Thorax 2008; 63: 72-77.
70. Moran F, Bradley JM, Piper AJ. Non-invasive ventilation for cystic fibrosis. Cochrane Database Syst Rev 2009; 1: CD002769.
71. Flight WG, Shaw J, Johnson S, et al. Long-term non-invasive ventilation in cystic fibrosis-experience over two decades. J Cyst Fibros 2012; 11: 187-192.